Dengue vaccine development: strategies and challenges

Area of Science:

• * Virology and Immunology
• * Infectious Diseases
• * Vaccinology

Background:

• * Dengue virus infection presents a significant global health threat, causing dengue fever or severe dengue hemorrhagic syndrome/shock.
• * Challenges include four distinct serotypes, vector control difficulties, lack of specific treatments, and the absence of a broadly effective vaccine.
• * Previous dengue virus exposure or vaccination can paradoxically increase disease severity upon subsequent infection, complicating vaccine development.

Purpose of the Study:

• * To review current dengue vaccine development strategies.
• * To identify obstacles hindering the creation of a safe and effective dengue vaccine.
• * To explore approaches for inducing a comprehensive immune response against all four dengue serotypes.

Main Methods:

• * Comprehensive literature review of dengue vaccine research and development.
• * Analysis of various vaccine platforms, including live attenuated, chimeric, DNA-based, subunit, and inactivated vaccines.
• * Evaluation of challenges related to serotype diversity, immune priming, viral interactions, and safety.

Main Results:

• * Multiple vaccine candidates are in various stages of preclinical and clinical development.
• * A significant hurdle is the risk of vaccine-induced immune enhancement, leading to more severe disease.
• * Achieving complete protection against all four serotypes requires overcoming complex immunological and virological challenges.

Conclusions:

• * Developing a tetravalent dengue vaccine remains a complex scientific challenge.
• * Further research is needed to address safety concerns and ensure broad efficacy against all serotypes.
• * Overcoming obstacles in vaccine design is crucial for controlling dengue virus transmission and disease burden.